Ypozane

RSS

osaterone acetate

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European Public Assessment Report. Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the Scientific Discussion (also part of the EPAR).

This EPAR was last updated on 05/11/2018

Authorisation details

Product details
Name
Ypozane
Agency product number
EMEA/V/C/000112
Active substance
osaterone acetate
International non-proprietary name (INN) or common name
osaterone acetate
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QG04CX90
Publication details
Marketing-authorisation holder
Virbac S.A.
Revision
3
Date of issue of marketing authorisation valid throughout the European Union
10/01/2007
Contact address

1ère Avenue 2065 M - L.I.D.
06516 Carros Cedex
France

Product information

25/10/2018 Ypozane - EMEA/V/C/000112 - IG/0984

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

UROLOGICALS

Therapeutic indication

Treatment of benign prostatic hypertrophy (BPH) in male dogs.

Assessment history

How useful was this page?

Add your rating